India In-Vitro Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

India in-vitro diagnostics market size in 2026 is estimated at USD 1.94 billion, growing from 2025 value of USD 1.82 billion with 2031 projections showing USD 2.66 billion, growing at 6.49% CAGR over 2026-2031. This report is Segmented by Test Type (Clinical Chemistry, and More), Technology (Polymerase Chain Reaction (PCR), and More), Product (Instruments, and More), Usability (Disposable IVD Devices, and More), Testing Site (Central Laboratory Testing, and More), Specimen Type (Blood, and More), Application, and End-User. The Market Forecasts are Provided in Terms of Value (USD).

India In-Vitro Diagnostics Market Trends and Insights

Rising Dual Burden of Communicable & Non-Communicable Diseases Necessitating Early Diagnostics

Tuberculosis still represents 27% of global cases traced to India, prompting a shift from microscopy to rapid molecular assays that offer higher sensitivity and same-day results. National Family Health Survey data show anemia prevalence of 57% among women and 67% among children under five, driving hematology test demand. Parallel growth of diabetes, now affecting 101 million citizens, and rising cardiovascular morbidity are pushing clinical chemistry and immunoassay volumes. Laboratories therefore broaden menus to run infectious disease panels alongside lipid, HbA1c, and cardiac marker testing on integrated platforms. Precision-oriented test adoption is accelerating in oncology as liquid biopsy assays identify actionable mutations without invasive biopsies, underlining why comprehensive diagnostics sit at the centre of India in-vitro diagnostics market development.

Expanding Health-Insurance Penetration & Disposable Incomes Enhancing Test Affordability

Insurance coverage has climbed from 25% to 51% of the population through flagship schemes such as Pradhan Mantri Jan Arogya Yojana. Reimbursement of laboratory procedures is lowering out-of-pocket spending and steering patients toward accredited sites. Growing volumes help labs amortise investments in high-throughput PCR, NGS, and chemiluminescence platforms, enabling price cuts that lure middle-income segments in tier-2 urban belts. Insurers are tightening quality criteria, compelling smaller centres to secure NABL accreditation or partner with organised chains. The resulting virtuous cycle of affordability, quality, and scale improves market depth across the India in-vitro diagnostics market.

Limited Cold-Chain & Logistics Infrastructure Restricting Rural Reagent Distribution

One-fifth of temperature-sensitive health products degrade because trucks and storage points cannot sustain 2-8°C. Portable battery-powered units like Phloton hold reagents at 4-6°C for 10 hours, but deployment is nascent. Widespread solar refrigeration roll-outs and passive insulated packaging are being tested to widen rural reach. Cold-chain gaps particularly hinder molecular and immunoassay expansion, slowing rural contribution to the India in-vitro diagnostics market.

Other drivers and restraints analyzed in the detailed report include:

• Government Investments in Public Laboratory Infrastructure under National Health Mission
• Adoption of High-Throughput Automation & AI in Laboratories Elevating Efficiency
• Fragmented Regulatory Approval Pathway Increasing Time-to-Market

For complete list of drivers and restraints, kindly check the Table Of Contents.

List of Companies Covered in this Report:

• Abbott Laboratories
• Roche
• Siemens Healthineers
• Transasia Bio-Medicals
• Thermo Fisher Scientific
• Beckton Dickinson
• bioMérieux
• Danaher
• Beckton Dickinson
• Arkray
• Bio-Rad Laboratories
• Agappe Diagnostics
• Mylab Discovery Solutions
• J Mitra & Co. Pvt Ltd
• HLL Lifecare Ltd (Hindlabs)
• SRL Diagnostics (Fortis Healthcare)
• Dr. Lal PathLabs Ltd
• Metropolis Healthcare Ltd
• Molbio Diagnostics (Truenat)
• Seegene

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support